Toxicidades sistêmicas simultâneas relacionadas à quimioterapia do câncer de mama: um relato observacional e prospectivo
DOI:
https://doi.org/10.31011/reaid-2022-v.96-n.40-art.1497Palavras-chave:
Quimioterapia, Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos, Neoplasias da Mama, Oncologia, EpidemiologiaResumo
Objetivo: avaliar quantitativamente um cluster de toxicidades sistêmicas relacionadas à quimioterapia em mulheres com câncer de mama ao longo do tratamento. Métodos: foi realizado um estudo observacional e prospectivo, de natureza quantitativa, envolvendo 140 mulheres com câncer de mama expostas à quimioterapia como modalidade de tratamento. A ocorrência de 14 toxicidades sistêmicas (baseadas no Common Terminology Criteria for Adverse Events, versão 4.03) foi avaliada nos prontuários médicos em dois segmentos: no ciclo intermediário e ao fim da quimioterapia. As frequências foram comparadas entre os dois segmentos do estudo, associando separadamente cada toxicidade e agrupando a quantidade de toxicidades simultâneas de cada paciente, considerando o nível de significância (p) de 5%. Resultados: observou-se que a maioria das toxicidades sistêmicas foram associadas entre os segmentos do estudo, bem como a maioria se manifestou com maior frequência ao final da quimioterapia. As toxicidades mais frequentes (considerando ambos os segmentos) foram vômito (90.7%), cefaleia (88.6%) e astenia (87.9%). As mais incomuns foram leucopenia (7.1%), neutropenia (13.6%) e parestesia (32.1%). Ao comparar a quantidade de toxicidades sistêmicas simultâneas entre os segmentos, observou-se um aumento significativo ao final da quimioterapia em relação ao ciclo intermediário (p <0.001). Conclusão: as mulheres com câncer de mama experimentaram uma quantidade maior de toxicidade sistêmicas simultâneas ao final da quimioterapia, bem como uma alta frequência de toxicidades sistêmicas ao longo do tratamento foi observada.
Downloads
Referências
Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am. 2014;32(1):167-203. doi: 10.1016/j.emc.2013.09.002.
Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3-23. doi: 10.2174/2211738507666190122111224.
Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. doi: 10.1186/s40659-017-0140-9.
Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, et al. Patient-reported toxicities during chemotherapy regimens in current clinical practice for early breast cancer. Oncologist. 2019;24(6):762-771. doi: 10.1634/theoncologist.2018-0590.
Monteiro AR, Garcia AR, Póvoa S, Soares RF, Macedo F, Pereira TC, et al. Acute toxicity and tolerability of anthracycline-based chemotherapy regimens in older versus younger patients with breast cancer: real-world data. Support Care Cancer. 2021;29(5):2347-2353. doi: 10.1007/s00520-020-05766-6.
Nyrop KA, Deal AM, Reeve BB, Basch E, Chen YT, Park JH, et al. Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. Cancer. 2020;126(13):3084-3093. doi: 10.1002/cncr.32898.
Prieto-Callejero B, Rivera F, Fagundo-Rivera J, Romero A, Romero-Martín M, Gómez-Salgado J, et al. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine (Baltimore). 2020;99(33):e21695. doi: 10.1097/MD.0000000000021695.
Malta M, Cardoso LO, Bastos FI, Magnanini MM, Silva CM. STROBE initiative: guidelines on reporting observational studies. Rev Saude Publica. 2010;44(3):559-65. doi: 10.1590/s0034-89102010000300021.
Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754-64. doi: 10.1001/jama.2008.824.
Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29(1):40-6. doi: 10.1200/JCO.2009.27.3011.
UNITED STATES OF AMERICA. Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v.4.03. Rockville: NCI; 2010.
Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022;155:131-166. doi: 10.1016/bs.acr.2022.02.007.
Kameo SY, Amorim BF, Barbosa-Lima R, Costa JS, Silva GM, Marinho PML, et al. Gastrointestinal toxicities in women during breast cancer chemotherapy treatment. Rev. Bras. Cancerol. 2021;67(3):e-151170. doi: 10.32635/2176-9745.RBC.2021v67n3.1170.
Tao G, Huang J, Moorthy B, Wang C, Hu M, Gao S, et al. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol. 2020;16(11):1109-1124. doi: 10.1080/17425255.2020.1815705.
Kameo SY, Barbosa-Lima R, Fonseca TV, Vassilievitch AC, Marinho PML, Sawada NO, et al. Dermatological alterations associated with oncological treatment of women with breast cancer. Rev. Bras. Cancerol. 2021;67(2):e-071133. doi: 10.32635/2176-9745.RBC.2021v67n2.1133.
Anoop TM, Joseph PR, Pn M, Kp P, Gopan G, Chacko S. Cutaneous toxicities in breast cancer patients receiving chemotherapy and targeted agents--an observational clinical study. Clin Breast Cancer. 2021;21(4):e434-e447. doi: 10.1016/j.clbc.2021.01.009.
Alizadeh N, Mirpour SH, Darjani A, Rafiei R, Rafiei E, Mohammadhoseini M. Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Int J Dermatol. 2020;59(7):822-828. doi: 10.1111/ijd.14916.
Tian W, Wang Y, Zhou Y, Yao Y, Deng Y. Effects of prophylactic administration of granulocyte colony-stimulating factor on peripheral leukocyte and neutrophil counts levels after chemotherapy in patients with early-stage breast cancer: a retrospective cohort study. Front Oncol. 2022;12:777602. doi: 10.3389/fonc.2022.777602.
Kasi PM, Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78(7):737-745. doi: 10.1007/s40265-018-0909-3.
Álvarez-Bustos A, de Pedro CG, Romero-Elías M, Ramos J, Osorio P, Cantos B, et al. Prevalence and correlates of cancer-related fatigue in breast cancer survivors. Support Care Cancer. 2021;29(11):6523-6534. doi: 10.1007/s00520-021-06218-5.
Palesh O, Scheiber C, Kesler S, Mustian K, Koopman C, Schapira L. Management of side effects during and post-treatment in breast cancer survivors. Breast J. 2018;24(2):167-175. doi: 10.1111/tbj.12862.
Ruiz-Casado A, Álvarez-Bustos A, de Pedro CG, Méndez-Otero M, Romero-Elías M. Cancer-related fatigue in breast cancer survivors: a review. Clin Breast Cancer. 2021;21(1):10-25. doi: 10.1016/j.clbc.2020.07.011.
Matoso LML, Rosário SSD, Matoso MBL. The care strategies for alleviating side effects of chemotherapy in women. Saúde (Sta. Maria). 2015;41(2):251-260. doi: 10.5902/2236583410883.
Costa AIS, Chaves MD. Pain in cancer patients under chemotherapy. Rev Dor. 2012;13(1):45-9. doi: 10.1590/S1806-00132012000100008.
Al Qadire M, Alsaraireh M, Alomari K, Aldiabat KM, Al-Sabei S, Al-Rawajfah O, et al. Symptom clusters predictive of quality of life among jordanian women with breast cancer. Semin Oncol Nurs. 2021;37(2):151144. doi: 10.1016/j.soncn.2021.151144.
So WKW, Law BMH, Ng MSN, He X, Chan DNS, Chan CWH, et al. Symptom clusters experienced by breast cancer patients at various treatment stages: a systematic review. Cancer Med. 2021;10(8):2531-2565. doi: 10.1002/cam4.3794.
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.